Milestone Pharmaceuticals Inc. (MIST) Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St steadies ahead of South Korean chip bellwether SK Hynix's debut
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Software stocks slide as Starbucks builds AI tools to replace vendor software
Milestone Pharmaceuticals Refreshes Board of Directors
July 15, 2024 8:00 AM EDT Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed
Third New Independent Director to Be Appointed to Board in Near Term
MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone or the Company), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced steps to refresh its Board of Directors (Board). Stuart Duty and Andrew Saik have been appointed to its Board, effective immediately, and will stand for election at the Companys 2024 Annual Meeting... More
